Invecchiamento cellulare e apoptosi: Relazione con la deprivazione androgenica del cancro della prostata. Articolo speciale di revisione

Tagarro A. : El reloj biológico. Cambio 16: 1263: 86, 1996.

Dimri G.P. , Campisi J. : Molecular and cell biology of replicative senescence. Cold Spring Harbor Symposia on Quantitative Biology, 59: 67, 1994.

Hubbard K. , Oza H.L. : Senescence and inmortalization of human cells. Cell growth and apoptosis: a practical approach. The practical approach series. IRC Press, 229, 1995.

Young I.D. : Development in genetics. British J. Urol., 75 (suppl. 1): 42, 1995.

Ramachandie S. , Studzniski G.P. : Morphological and biochemical criteria of apoptosis. Cell growth and apoptosis: a practical approach. The practical approach series. IRC Press, 119, 1995.

Baselga R. : Measuring parameters of growth. Cell growth and apoptosis: a practical approach. The practical approach series. IRC Press, 229, 1995.

Gaffney E.F. : The extent of apoptosis in different types of high grade prostatic carcinoma. Histopahtology, 25: 269, 1994.

Furunya Y. , Isaacs J.T. : Differential gene regulation during programmed death (apoptosis) versus proliferation of prostatic glandular cells induced by androgen manipulation. Endocrinology, 133 (6): 2660, 1993.

Mottaz A.E. , Markwaldes R. , Fey F.M. , Klima I. , Merz V.W. , Studa V.E. : Abnormal p53 expression is infrequent in clinically localized human prostate cancer and in bening prostatic hyperplasia (BPH). Abstract, AUA 1995.

Harris D.R. , Savill J. : Apoptosis and the prostate. British J. Urol., 75 (suppl. 1): 27, 1995.

Buttyan R. Schmmer , Colombel M. , Olsson C.A. : Prostate cell proliferation and programmed death share an early molecular pathsvay regulated by androgens. Oncogens and molecular genetics of urological tumours. Churchill-Livingstone, 1992.

Feng J. : The RNA component y human telomerase. Science, 269: 1236, 1995.

Goletz T.J. , Smith J.R. , Pereira Smith O.M. : Molecular genetic approaches to the study of cellular senescence. Cold Spring Harbor Symposia on Quantitative Biology, 59: 59, 1994.

Willye Alt. , Kerr J.F.R. , Currie A.R. : Cell death: the significance of apoptosis. Int. Rev. Cytol., 68: 251, 1980.

Monti D. : Apoptosis. Programmed cell death: a role in the aging process? Am. J. Clin. Nutr., 55 (suppl. 6): 1208, 1991.

Zakian V.A. : Telomeres begining to understand the end. Science, 270: 1601, 1995.

Blackcburn E. : Structure and function of telomeres. Nature, 350: 569, 1991.

Greider C.W. , Blackburn E.H. : Telomeres, telomerasa y cancer. Investigation ciencia, 20 abril 1996.

Haber D.A. : Telomeres, cancer an inmortality. New England J. Med., 332/14: 995, 1995.

Allsopp R.C. : Telomere lenght predicts replicative capacity of human fibroblast. Proc. Nat. As. Sc., 89 (10): 114, 1992.

Kim N.W. : Specific association of human telomerase activity with inmortal cells and cancer. Science, 266: 2011, 1994.

Harley C.B. : Telomerase an cancer. Cold Spring Harbor Symposia in Quantitative Biology, 59: 307, 1994.

Kerr J.F.R. , Wyllie A.H. , Currie A.R. : Apoptosis: a basic biological phenomenon with wide ranging implications in tissue cinetics. British J. Cancer, 26: 239, 1972.

Oberhammer F. : Apoptosis and cromatine degradation. European Molecular Biology Organization Journal (EMBO) 12: 371, 1993.

Ellis R.E. , Yuan J. , Horwitz Hr. : Mechanisms and function of cell death. Ann. Rev. Cell. Biol., 7: 663, 1991.

Savill J. , Padok V.A. , Henson P.M. , Harlett C. : Phagocyte recognition of cells undergoing apoptosis. Inmunol. Today, 14: 131, 1993.

Symonds H. : p53 dependent apoptosis suppressor tumour growth and progression in vivo. Cell., 78: 703, 1994.

Almansar A. : Deficiency of retinoblastoma protein leads to innappropiate S-phase entry activation to E2F responsive genes and apoptosis. Proc. Nat. Accid. USA, 92 (12): 5436, 1995.

White E. : p53, guardian of rB. Nature, 371: 21, 1994.

Graeber T.G. , Osmanian C. , Jacks T. , Housman D.E. , Koch C.J. , Lowe S.W. , Giaccia A.J. : Hipoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature, 379: 88, 1976.

Nasgata S. , Goldstein P. : The fas death factor. Science, 267: 1449, 1995.

Periman H. , Zahng S. , Raffo A. , Brittyan R. : Increassed bax/bcl-2 ratio correlates with the onset of apoptosis in the castrated rat ventral prostate gland. Abstract, AUA 1995.

Hockerbery D.M. : Bcl-2 functions an antiooxidant pathway to prevent apoptosis. Cell., 75: 241, 1993.

Bisonnette R.P. , Echeverri F. , Mahbonb A. , Green D.R. : Apoptotic cell death induced by c-Myc is inhibited by vcl-2. Nature, 359-552, 1992.

Colombell M. : Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone refractary human prostate cancer. Am. J. Pathol., 143 (2): 399, 1993.

Pandha H.S. , Sikoza K. : Gene therapy for urological cancer. British J. Urol., 75 (suppl. 1): 67, 1993.

Raffo A.J. , Perlman H. , Chen M.W. , Day M.L. , Steifman J.S. , Buttyan R. : Over-expression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.

Ayyagasi S.R. , Suea W. , Campbell R. , Nelson W.G. , Simons J.W. , Carducci M.A. : Phenylbutyrate a novel componid for human prostate cancer therapy, induces apoptosis and has a cytotoxic effects more potent than phenilacetate. Abstract, AUA 1995.

Vucakovic J. , Isaacs J.T. : Human prostate cancer cells are sensitive to programmed (apoptosic) death induce by the antiangiogenic agent linomide. Cancer Res., 55: 3517, 1995.

Sommerfeld H.J. et al.: Abstract 963, AUA 1995.